heart disease News
-
iVascular SLU, Barcelona Invests in NaviGate Cardiac Structures, Inc.
At the end of 2018, iVascular SLU, a European medical device company, made an investment in NaviGate Cardiac Structures, Inc. and will be instrumental in helping the company’s developments by providing its expertise in fabrication and manufacturing of various components of our atrioventricular valved stent bioprosthesis system. This will be a very fruitful association that will ...
-
Jiffy Lube surpasses $1 million fundraising goal for the American Heart Association`s go red for women movement to fight heart disease
As a result of the generous support of its customers across the country, Jiffy Lube proudly announces that its 2010 Maintenance Partners for Life campaign raised more than $1 million for the American Heart Association's (AHA) Go Red For Women movement -- for a third year. More than 1,700 Jiffy Lube service centers participated in the campaign, which helps raise awareness and funds to fight heart ...
-
Pipelife around the world - Finland
In the course of our group-wide charity project, Pipelife Finland has divided its donation in two parts in order to support two organizations: the Northern Ostrobothnia Heart Association and the Save the Children Foundation. The Northern Ostrobothnia regional heart association is a part of the Finnish Heart Association and promotes heart health of the inhabitants of Northern Osthrobothnia. The ...
-
ATsens recruited Lee Man-yeong, Professor of Catholic University College of Medicine, as CMO and the head of data center
ATsens developed the first wearable long-term continuous ECG monitor in Korea. Honorary professor Lee Man-Yeong was appointed as CMO and head of the data center for medical advice and data center establishment. He’s a professor of Circulatory Internal Medicine and an authority in the field of arrhythmia, who continued research and treatment of arrhythmia during his tenure. Participate ...
-
Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for th e Treatment of Chronic Heart Failure
Hanover, Germany, December 11, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School ...
-
Showcase
Revolutionising Cardiovascular Health: Monitoring the Surface Metallurgy of Stents
In a ground-breaking advancement for cardiovascular care, Hiden Analytical Ltd is proud to announce a surface measurement technique for devices critical in the treatment of heart disease. Utilizing the most sensitive surface analysis technology, Secondary Ion Mass Spectrometry (SIMS), Hiden Analytical is setting new standards in the safety, efficacy, and innovation of stent technology. Surgical ...
-
Dr. Dwyer joins Coala Life Inc. as new Chief Medical Officer
Coala Life today is pleased to announce the appointment of Jerome V. Dwyer, MD, MBA as Chief Medical Officer – Coala Life, Inc. Dr. Dwyer will oversee the continued development of Coala’s patient-centric solutions that use smart algorithms to digitally transform the field of cardiac diagnostics and help win the battle against the world’s leading cause of death—heart ...
-
Cardior`s pioneering miRNA approach in heart failure endorsed by expert opinions in the European Heart Journal
Hanover, Germany, February 9, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two editorials from ...
-
EPA Releases New PSA for American Heart Month
Today, the U.S. Environmental Protection Agency (EPA) issued a new Public Service Announcement (PSA) to educate the public and healthcare providers about the risks of air pollution to the heart. "Over more than four decades of EPA history, we've made tremendous progress cleaning up the air we breathe by using science to understand the harmful effects of air pollution," said EPA Administrator ...
-
Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart
Hanover, Germany, June 24, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in the treatment of cardiac diseases were published in the Journal of ...
-
Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programs for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally
Genome Biologics UG, Frankfurt, Germany, today announced that they have been awarded up to 9.8 million euros of equity funding through the European Innovation Council (EIC) Accelerator program to accelerate their breakthrough innovations in cardiovascular drug discovery and development. Cardiovascular diseases account for the majority of mortality and disability globally, accounting for 32% of ...
-
Novel Modulators of LDL Metabolism
DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are achieving the low ...
-
Study: BPA May Increase Risk of Heart Disease
A recent study published in Circulation has linked heart disease with bisphenol A (BPA), the controversial industrial chemical that is ubiquitous in plastics, resins, paint, can linings, and other products, reports Time. Examining data from a long-running British health survey, researchers discovered that people who had heart disease also tended to have higher urinary concentrations of BPA. ...
-
Structure-Based Search for Novel Antihypercholestrolemic Agents
DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are ...
-
Ginsenosides: a new offering with ancient roots
POS Analytical Services now offers quantitative analysis of ginsenosides, a class of steroid glycosides considered to be the biologically active component of ginseng. Discovered more than 5,000 years ago, Chinese herbalists have prescribed ginseng for everything from normalizing blood pressure to improving blood circulation to preventing heart disease for centuries. Ginsenosides in particular ...
-
How Willem Einthoven gave doctors a window on the heart
If the doctor has ever placed electrodes on the skin to record a trace of a heartbeat, then thanks to this gentleman - Willem Einthoven. His invention, the electrocardiogram IECG), has been used for over 100 years and is still one of the most commonly used diagnostic tools in medicine. He became interested in electrical heart activity after watching a demonstration of a raw electrocardiogram ...
-
Bodyport Appoints Amit Rushi as Chief Commercial Officer and Phyllis Whiteley, Ph.D. as Chair of the Board of Directors
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
-
Revacept - an innovative vascular plaster proved in coronary heart disease
The novel drug Revacept can reduce heart attacks and strokes more efficient and safer than previous standard therapies. This is the result of a study in an investigator initiated study in patients carried out with the German Center for Heart and Circulation Research (DZHK). The study was recently published in JAMA Cardiology. With Revacept severe complications such as heart attacks and stroke in ...
-
Coming soon: EPA’s 48-hour burn wise video contest
The U.S. Environmental Protection Agency is sponsoring a video contest for professional and amateur filmmakers on Burn Wise, the agency’s campaign to help citizens reduce pollution from their fireplaces and other wood-burning appliances. With the theme “Learn Before You Burn,” the winning 30- or 60-second videos will promote responsible wood-burning techniques that can help citizens save money ...
-
Presenting Monogenic Heart Failure Disease Modeling in Kyoto
https://www.termis.org/wc2018/ On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session. 99-O-5: Personalized micro-3D human heart tissues for orphan drug development Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli, Michael Greenberg,Jennifer Strande InvivoSciences, Inc. Madison Wisconsin, USA, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you